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Abstract
Background: High blood pressure (HBP) is a major risk factor for cardiovascular disease (CVD). European
hypertension and cardiology societies as well as expert committees on CVD prevention recommend stratifying
cardiovascular risk using the SCORE method, the modification of lifestyles to prevent CVD, and achieving good
control over risk factors. The EDUCORE (Education and Coronary Risk Evaluation) project aims to determine
whether the use of a cardiovascular risk visual learning method - the EDUCORE method - is more effective than
normal clinical practice in improving the control of blood pressure within one year in patients with poorly
controlled hypertension but no background of CVD;
Methods/Design: This work describes a protocol for a clinical trial, randomised by clusters and involving 22
primary healthcare clinics, to test the effectiveness of the EDUCORE method. The number of patients required was
736, all between 40 and 65 years of age (n = 368 in the EDUCORE and control groups), all of whom had been
diagnosed with HBP at least one year ago, and all of whom had poorly controlled hypertension (systolic blood
pressure ≥ 140 mmHg and/or diastolic ≥ 90 mmHg). All personnel taking part were explained the trial and trained
in its methodology. The EDUCORE method contemplates the visualisation of low risk SCORE scores using images
embodying different stages of a high risk action, plus the receipt of a pamphlet explaining how to better maintain
cardiac health. The main outcome variable was the control of blood pressure; secondary outcome variables
included the SCORE score, therapeutic compliance, quality of life, and total cholesterol level. All outcome variables
were measured at the beginning of the experimental period and again at 6 and 12 months. Information on sex,
age, educational level, physical activity, body mass index, consumption of medications, change of treatment and
blood analysis results was also recorded;
Discussion: The EDUCORE method could provide a simple, inexpensive means of improving blood pressure
control, and perhaps other health problems, in the primary healthcare setting;
Trial registration: The trial was registered with ClinicalTrials.gov, number NCT01155973 [http://ClinicalTrials.gov].
* Correspondence: eescortell.gapm03@salud.madrid.org
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High blood pressure and cardiovascular disease
In the year 2000, the worldwide prevalence of high
blood pressure (HBP) among the adult population was
26.4% [1]. The highest prevalence figures are seen in the
most developed regions - about 44% in Europe and 28%
in the USA [2]. In Spain the figure is around 35%,
reaching as high as 60% in people over 60 years of age
[3]. This high prevalence is associated with increased
rates of premature mortality and incapacity. Hyperten-
sion was responsible for 7.6 million early deaths in 2001
(13.5% of total mortality), along with 92 million cases of
incapacity (6% of the total), and it is thought to be the
cause of 54% of all strokes and 47% of all cases of
ischaemic heart disease [4]. In Spain, over 30.0% of all
deaths are owed to HBP [3]. The prospects for the
future are even worse; it is believed HBP figures for the
year 2025 will show a 60% increase over those of 2000
[1]. An ageing population, improvements in treatment
and a growing epidemic of obesity underlie this
expected increase [1,3,5].
Control of HBP
The control of HBP in Europe is far from optimum
[6-8], and in southern Europe the proportion of hyper-
tensive subjects who are under treatment and being
monitored is smaller than in the continent’s north [9].
The CONTROLPRES studies, undertaken in Spain in
the primary healthcare setting, have, however, shown
some improvement; between 1990 and 2003 the number
of people in whom good control of HBP was achieved
increased by 25% [10]. This amelioration was confirmed
in the PRESCAP 2006 study [11], in which control was
achieved in 40%, rising to 44% in the recently published
(2009) MADRIC study [12]. However, the figures clearly
show there is room for further improvement. Among
the causes of poor control of HBP are late detection, the
late start of treatment, poor treatment compliance (a
common problem in patients with chronic conditions)
[13] and clinical or therapeutic inertia [13-15].
Calculating cardiovascular risk as a clinical and preventive
strategy
In recent years, many studies have investigated the use
of tables based on the Framingham study [16-19] (e.g.,
the Anderson, Wilson, DORICA or REGICOR tables)
for calculating cardiovascular risk (CVR). However,
since 2003 the tables produced by the SCORE project
have been recommended for use in Europe. These are
derived from data harvested from 12 cohorts of patients,
one of which is Spanish [20]. Although the calibration
of the SCORE table for use in Spain was published in
2007 [21], the fourth European Cardiovascular Disease
Prevention in Clinical Practice Guidelines [22], along
with their adaptation by the Spanish Interdisciplinary
Committee for Cardiovascular Prevention (Comité Espa-
ñol Interdisciplinario para la Prevención Cardiovascular:
CEIPC) [23], recommend the use of the low risk SCORE
table [22,23]. The healthcare instructions issued by the
Madrid Region (Comunidad de Madrid; Revision 2009)
[24] recommend the same [available at: http://www.
madrid.org].
In randomised clinical trials, several strategies aimed
at health professionals and patients have been shown
capable of improving compliance with antihypertension
therapy [25] and of reducing therapeutic inertia [26].
The best would seem to target both [27]. These have
l e dt od o c u m e n t e di m p r o v e ments in blood pressure
[28,29], changes in lifestyle [30], reduced coronary risk
and reduced overall cardiovascular mortality [31].
As a strategy, improving the perception of risk is clo-
sely related to making behavioural changes that affect
health [32]. Leal et al. [33] report how an intervention
that showed patients their CVR, assessed using the Fra-
mingham model, reduced this risk within one year. This
was particularly true for patients at high or very high
risk. In addition, in the IMPALA study, which examined
the effectiveness of a nursing intervention on the per-
ception of CVR calculated using the SCORE method,
CVR fell significantly in the intervention group and, in
fact, in the control group [34,35].
Ways of communicating CVR to patients
It is unclear which communication format (graphs,
tables, percentages or rates) is the best to use in educa-
tional interventions, although each type has its own
advantages [36]. Some authors suggest visual formats
m a yb et h eb e s tw a yt od e s c r i b et h er i s k sa n db e n e f i t s
of treatment [37] since effectiveness is not conditioned
by the mathematical knowledge or general educational
level of the patient [38]. Probabilistic information
offered via a pictogram was found to be particularly use-
ful with patients of low educational level when assessing
the risks and benefits of pharmacological treatment [39],
and communication via icons and matrices has been
reported more precise than the use of percentages, inde-
pendent of recipient educational level or age [40].
Affective communication can improve the perception
of risk in high risk patients, and alleviate concerns in
those whose risk is low [41]. The EDUCORE method
(Education and Coronary Risk Evaluation) may provide
a means of facilitating such communication. This
method was developed following a proposal by one of
the present authors and has been informally tested in
patients at a primary healthcare centre over the course
of a year.
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The aim of the present work is to determine whether the
EDUCORE method for communicating cardiovascular risk
in patients with poorly controlled HBP, but no history of
CVD, is more effective than normal practice in terms of
improving the control of blood pressure at one year.
Methods/Design
Study characteristics
The present work involves a two-year community, paral-
lel clinical trial, randomised by clusters. Twenty two pri-
mary healthcare centres (PHCC) in the Madrid Region
(Comunidad de Madrid) took part. The recruitment of
these centres was undertaken between March and May
2009. The research group was comprised of 166 per-
sons: 148 general practitioners and nurses (clinical assis-
tance group), and 19 scientific researchers (technical
group). A member of the clinical assistance team at
each participating centre was appointed as liaison officer
between the centre and the technical group.
The study protocol was approved by the Area 3
Research Ethics Committee (Comité de Ética de Investi-
gación Clínica del Área 3) (2009/24/06), and met all
good clinical practice demands. The trial was registered
with ClinicalTrials.gov, number NCT01155973 [http://
ClinicalTrials.gov].
The actual patient recruitment started on June 1st,
2010.
Patients
1. Inclusion criteria. All patients were required to be:
a. Attending patients diagnosed with HBP (systolic
blood pressure ≥ 140 mmHg and/or diastolic blood
pressure ≥ 90 mmHg) at least one year ago, with
analytical (complete biochemical, cholesterol, serum
creatinine and microalbuminuria results) and ECG
results available, whose blood pressure was poorly
controlled (last determination systolic ≥ 140 mmHg
and/or diastolic ≥ 90 mmHg), and for whom infor-
mation on organ involvement was available.
b. Aged 40-65 years.
c. To be able to meet the demands of the trial, i.e.,
to have no intention of moving, to be localisable for
the next year, and to have the capacity to under-
stand the questionnaires presented.
d. To have given signed, informed consent to be
included in the study, and to meet no exclusion
criterion.
2. Exclusion criteria. Patients were required not to
have suffered a major cardiovascular event (cerebrovas-
cular accident, heart disease, kidney disease, peripheral
artery disease, advanced retinopathy [grades III/IV]), or
to be suffering diabetes mellitus, a serious chronic dis-
ease with a notable impact on physical or psychological
status (immobility patients, multi-system disease, serious
deterioration of quality of life owed to chronic disease),
or to be unable to collaborate (patients with dementia
or other psychopathologies).
Randomisation
Sampling was performed by clusters, the PHCCs being
the randomisation units. This minimised possible con-
tamination effects between centres. An independent sta-
tistician randomly assigned the 22 PHCCs (each of
which were randomly assigned a code) to either the
EDUCORE method group or a control (normal practice)
group (11 centres in each group) using Epidat 3.1
software.
Consecutive patients were chosen to minimise the risk
of bias in their selection. Figure 1 shows the process fol-
lowed (Figure 1. Patients’ recruitment). During consulta-
tions, patients were informed about the study and asked
whether they would like to take part. Those who
accepted were asked to give their signed consent, and
checks were made to ensure they met all inclusion
criteria but no exclusion criterion.
Sample size
Method of calculation. For an alpha of 0.05, a power of
80%, and in order to detect an increase in good control
of blood pressure of 15% in the EDUCORE group, the
overall sample size required was 354 patients (177 in
each arm of the study). Since randomisation was by
clusters, the sample size had to be larger than if simple
randomisation had been performed, in order to take
into account the design effect (DE). The DE was calcu-
lated as follows: DE = 1 + (nc -1 )*I C C( w h e r en c is
the mean number of individuals in the cluster, and ICC
the intracluster correlation coefficient) [42]. Bearing in
mind that the ICC range for trials randomised by clus-
ters involving systolic blood pressure is 0 - 0.052 [42],
the ICC in the present work was deemed to be 0.03.
The mean cluster size was assumed to be 30 patients.
Given these assumptions, and expecting a 10% loss rate
at one year, the final sample size required was 736
patients (368 in each arm).
Masking
In a study of this type it is impossible to mask the inter-
vention. To mask the analysis of data, the persons
charged with this task were blind to the arm to which
each PHCC had been assigned.
The intervention
Before beginning the field work, all the healthcare pro-
fessionals taking part attended a number of training
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members of the technical group explained the work to
the liaison officers. This was followed by 2-3 h sessions
aimed at the members of the clinical assistance teams
at each of the participating centres. These sessions dis-
cussed the methodology of the study, the interventions
(the EDUCORE method and normal practice), the
work plan (organisation and data collection), the
storage of data, and ethical, legal and authorship
questions.
Table 1 summarise the steps followed at each appoint-
ment. Patients attended five appointments over the time
of the study period. Each appointment lasted 10-30 min.
Normal practice group
The steps followed in the control arm included:
1. Use of low risk SCORE table [23]:
a. Calculation of CVR at appointments 1, 3 and 5 (at
the beginning of the experimental period and again
at 6 and 12 months).
Patients with high blood pressure, diagnosed gp , g
at least one year ago, aged 40-65 years
Inform about study
Agrees to 
take part?
No
Provide
Yes REJECTION
Provide
signed, dated 
consent
EXCLUSION No
EXCLUSION No
Yes
Inclusion
criteria met?
Yes
Exclusion 
criteria met?
Yes EXCLUSION
Organ damage and/or 
abnormal clinical 
examination?
Yes EXCLUSION
No INCLUSION
Figure 1 Patients’ recruitment.
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age for all patients under this age.
2. Verbally informing the patient of his/her CVR.
Neither the low risk SCORE table nor any other visual
aid (images, graphs, tables) was shown to the patients
until the end of the study (appointment 5).
3. Giving advice/verbal information on risk factors.
The criteria followed for the assessment and control
of CVR were those published by the Madrid Regional
Health Service (available at: [http://www.madrid.org/cs/
Satellite?
cid=1142584869941&language=es&pagename=PortalSa-
lud%2FPage%2FPTSA_pintarContenidoFinal&vest=
1142584869941] [24].
The EDUCORE intervention group
The steps followed in the EDUCORE arm included:
1. Use of low risk SCORE table [23]:
a. Calculation of CVR at appointments 1, 3 and 5 (at
the beginning of the experimental period and again
at 6 and 12 months).
b. Calculation of the projected CVR at 60 years of
age for all patients under this age.
Table 1 Actions at each patient appointment
Appointment 1
Recruitment: may require an extra patient appointment to collect all the information necessary
for a decision on inclusion/exclusion to be made, to inform the patient about the study, and to
request signed consent to be included. See Figure 1.
Actions performed in both study arms (GP/nurse) Additional actions performed in the
EDUCORE arm (GP)
Collection of sociodemographic data: sex, age, educational level, physical activity, use of tobacco,
consumption of medications, body mass index.
Use of EDUCORE method.
Taking of blood pressure. Completion of MiniCHAL and Morisky-Green questionnaires.
Calculation of SCORE score and extrapolation to 60 years of age.
Define interventions and therapeutic objectives for CVR, HBP, total cholesterol and tobacco use
At the end of the appointment, inform patient of therapeutic plan (pharmacological/non-
pharmacological). Record changes in drugs prescribed.
Appointment 2 (at 3 months)
Actions in both arms (GP/nurse) No additional actions in the EDUCORE
arm
Record blood pressure and degree of control.
Review pharmacological treatment.
Appointment 3 (at 6 months)
Actions performed in both study arms (GP/nurse) Additional actions performed in the
EDUCORE arm (GP)
Record blood pressure and degree of control. Completion of Morisky-Green questionnaire. Use of EDUCORE method.
Review pharmacological treatment.
Calculation of SCORE score and extrapolation to 60 years of age.
Appointment 4 (at 9 months)
Actions in both arms (GP/nurse) No additional actions in the EDUCORE
arm
Record blood pressure and degree of control.
Review pharmacological treatment.
Appointment 5 (at 12 months)
Actions performed in both study arms (GP/nurse) No additional actions in the EDUCORE
arm
Record blood pressure and degree of control.
Completion of MiniCHAL and Morisky-Green questionnaires.
Record physical activity and changes in number of packets of cigarettes smoked/year in smokers.
Calculation of SCORE score and extrapolation to 60 years of age.
Perform annual blood analysis. Review pharmacological treatment.
Record changes in clinical variables (consumption of medications, body mass index).
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images embodying different stages of a high risk action
using the consultation room’s computer with the aim of
increasing consciousness regarding risk-entailing habits.
3. Handing the patient a pamphlet.T h i sp a m p h l e t
contained advice on how to maintain cardiovascular
health plus the low risk SCORE table with the patient’s
current score marked.
Variables
Outcome variables
The main outcome variable measured in both groups
was the control of blood pressure (systolic blood pres-
sure < 140 mmHg and dyastolic blood pressure < 90
mmHg). The blood pressure was determined using the
Riva-Rocci method and listening for Korotkoff sounds,
using validated and calibrated sphygmomanometers).
The secondary outcome variables recorded were: CVR
(measured using the low risk SCORE table), total cho-
lesterol level, the use of tobacco, therapeutic compliance
(measured using the Morisky-Green treatment compli-
ance questionnaire) [43], and quality of life (measured
using the miniCHAL quality of life questionnaire vali-
dated for use with patients with HBP) [44].
Sociodemographic variables recorded
These included sex, age and level of education (low, pri-
mary studies only; medium, high school completed,
technical training or other non-university studies com-
pleted; high, university level education completed).
Patient physical activity was measured using a question-
naire (recorded in metabolic equivalent hours per week)
[45].
Clinical variables recorded
These included body mass index (weight in kg/height in
cm
2), use of tobacco (current smoker, ex-smoker, never
smoker; smokers were asked to declare the number of
packets smoked per year), total cholesterol and LDL-
cholesterol (mg/dl), serum creatinine (mg/dl) and micro-
albuminuria/creatinine (mg/g). The consumption of car-
diovascular medication (angiotensin converting enzyme
inhibitors, angiotensin II receptor antagonists, diuretics,
beta blockers, alpha blockers, renin direct inhibitors,
and lipid lowering drugs) at the beginning and end of
the study was also recorded. Changes in medication
were also recorded, as were the reasons for such change,
including secondary effects and ineffectiveness. The type
of change made to antihypertension treatment was also
recorded, including increasing/reducing dose, drug asso-
ciations, suspensions and substitutions.
All data (excluding patient identification data) were
recorded in an electronic database (previously validated
in preliminary studies) se a r c h a b l eo n l yb yt h eE D U -
CORE group via a corporative intranet system. This
centralised the collection of data, facilitating later
analysis.
Variables recorded for health professionals
These included sex, age, professional category (general
practitioner, nurse), the date of qualification, and the
PHCC where services were rendered. This facilitated the
description of the clinical assistance personnel asso-
ciated with each cluster.
Patients who declined to participate
The number of patients who declined to participate was
recorded, as required by the CONSORT statement [46].
Losses and withdrawals
The causes of all losses and withdrawals (voluntary
withdrawal, change of residence, comorbidity or death,
cause of death [cardiovascular or other]) were recorded.
When patients failed to attend an appointment, two
attempts were made to enter into contact by telephone.
Researcher communication
A web page was used to facilitate the monitoring of the
work performed and to make the project more visible
http://www.educore.es.
Analysis
The use of randomisation by clusters conditions the sta-
tistical analysis that can be employed, especially in the
calculation of confidence intervals and the testing of
hypotheses. The following analyses were undertaken:
1. Descriptive analysis and the description of the pro-
file of patients who abandoned the study plus their rea-
son for withdrawal.
2. Baseline comparison of the two intervention
groups in terms of the analytical variables measured,
prognostic factors and descriptive variables, using appro-
priate bivariate statistical tests.
3. Effect of the EDUCORE method on blood pres-
sure control (main outcome variable): i.e., a compari-
son of the proportion of patients with good/bad control
in the two study arms using the Chi-squared test, and
the calculation of confidence intervals at 6 months and
1 year after patient inclusion. Logistic regression with
random effects was used to adjust for prognostic factors;
the dependent variable was good/bad control of patient
blood pressure, and the independent variable the inter-
v e n t i o ng r o u pt ow h i c he a c hp a t i e n tb e l o n g e d .C o n -
founding factors or factors that might alter the effect
recorded were taken into account in this analysis.
4. Effect of the EDUCORE method on secondary
outcome variables (CVR, cholesterol levels, use of
tobacco, therapeutic compliance and quality of life)
using appropriate statistical tests.
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treat. The ‘last observation carried forward’ was used for
missing data [47]. Significance was set at P < 0.05. All
calculations were made using SPSS
© v.18 software.
Discussion
Educational intervention strategies aimed at either
patients or health professionals can provide benefits in
the control of HBP [27,31,33]. The visual presentation
of risk for different health problems, and using different
formats, can improve the comprehension of risk and the
motivation on the part of patients to change their life-
styles [32]. The EDUCORE method, which aims to
improve the control of HBP by targeting both patients
and health professionals, is simple, economic, and
makes use of computer facilities already available in
consultation rooms. If it proves to be effective, it might
be used with certain other chronic diseases managed at
PHCCs, perhaps providing further benefits to commu-
nity health.
The study design used in this work is, however, sub-
ject to certain limitations. Firstly, the intervention can-
not be masked, which could influence the assessment of
its effect. Certainly, the possibility of contamination
exists if the patients involved communicate with one
another [46]. For this reason randomisation by clusters
was employed. It was assumed that the number of clus-
ters was sufficient for the random assignment of PHCCs
to one arm or the other to compensate for such poten-
tial confounding factors.
In practice, the percentage of patients with good con-
trol of their HBP that can be reached, though improva-
ble, is limited. Thus, achieving a very large impact with
the EDUCORE method might be difficult. For this very
reason, any positive effect achieved - even though small
in magnitude - could be understood to represent suc-
cess, especially in this disease of such great pubic health
importance.
The conclusions drawn from this study might influ-
ence clinical practice and research into blood pressure
control. In the clinical setting, the reduction of CVR in
patients with HBP could have an important effect on
health and quality of life.
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